Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Oxford BioDynamics ( (GB:OBD) ) just unveiled an update.
Oxford BioDynamics PLC has announced a fundraising initiative to raise at least £6 million through a combination of placing, subscriptions, and a WRAP Offer. The proceeds will be used as working capital to support the commercial development of their EpiSwitch® product line. This move is strategic for the company, as it aims to strengthen its market position by increasing revenue through partnerships and collaborations. The fundraising is contingent on shareholder approval, and it underscores the company’s commitment to expanding its innovative diagnostic solutions and enhancing its financial stability.
More about Oxford BioDynamics
Oxford BioDynamics PLC is a precision clinical diagnostics company that focuses on providing specific and sensitive medical tests using its EpiSwitch® 3D genomics platform. The company has launched clinical diagnostic products like the EpiSwitch® Prostate Screening Test and EpiSwitch® CiRT for cancer, with a development pipeline for other conditions. They aim to advance personalized healthcare through partnerships and collaborations with diagnostic and pharmaceutical companies.
YTD Price Performance: -40.0%
Average Trading Volume: 4,651,142
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.91M
See more data about OBD stock on TipRanks’ Stock Analysis page.
